Charles river laboratories international, inc. updates tumor model compendium

Charles river laboratories international, inc. announced updates to its online tumor model compendium. charles river’s cancer model database provides access to a comprehensive collection of well-established tumor models for early-stage oncology research. this update adds 79 new patient-derived xenografts (pdx), 10 new cell line-derived xenografts (cdx), and 36 new cell line (cl) models for several cancer types including: anal, colon, lung and renal cancer as well as leukemia and melanoma. additionally, the update provides an increased depth of data for both whole exome sequencing (wes) and gene expression, with greater bioinformatics coverage: 71 new wes data sets, increasing whole exome data to 90% of models. 92 new rna-seq data sets, increasing gene expression data to 87% of models. charles river’s compendium includes tumor models from a wide range of tumor subtypes for both in vivo and in vitro oncology research, including patient-derived xenografts (pdxs), cell line-derived xenografts (cdx), and syngeneic models. this resource allows researchers to easily identify the most appropriate tumor models, leading to a more targeted study design from the start, saving time and money on the path to the clinic. the compendium, when combined with charles river’s robust portfolio of oncology services and scientific background, provides a highly translational platform for developing safe, effective oncology therapeutics.
CRL Ratings Summary
CRL Quant Ranking